DCF Advisers’s iShares Biotechnology ETF IBB Stock Holding History

DCF Advisers’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,000	Closed	-$353K	–	83
2022 Q2	$353K	Sell	3,000 -4,000	-57%	-$475K	0.21%	54
2022 Q1	$912K	Buy	+7,000	New	+$912K	0.4%	45
2020 Q4	–	Sell	-10,000	Closed	-$1.35M	–	95
2020 Q3	$1.35M	Buy	+10,000	New	+$1.36M	0.69%	33

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

DCF Advisers's IBB Position: Q3 2022 in Review

DCF Advisers sold out of iShares Biotechnology ETF (IBB) in Q3 2022, closing a stake of 3,000 shares — an estimated $353K sold.

DCF Advisers first reported a position in IBB in Q3 2020 and held it in 3 quarters. The position peaked at $1.35M in Q3 2020. 830 funds tracked by Wall St. Rank hold IBB as of Q3 2022.

DCF Advisers reported no remaining iShares Biotechnology ETF position as of Q3 2022 after selling out during the quarter.
DCF Advisers sold 3,000 iShares Biotechnology ETF shares in Q3 2022, an estimated $353K.
DCF Advisers first reported a position in iShares Biotechnology ETF in Q3 2020 and held it in 3 quarters.
DCF Advisers's iShares Biotechnology ETF position peaked at $1.35M in Q3 2020.
830 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2022.

Based on DCF Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.